We explored that with age over 60, KMT2D, PIM1, and CREBBP were frequently mutated in EBV-negative patients, while MYD88, ID3, and FOXO1 highly altered in EBV+ DLBCL group. This evidence concerns the gene KMT2D and diffuse large B-cell lymphoma.